Abstract 251P
Background
According to data of Globocan 2018 year, 18.1 million of new cancer cases have been registered and more than half of these cases occur in the Asian continent. Moreover, among women, cervical cancer takes the 4th place in morbidity and mortality. In the Republic of Uzbekistan cervical cancer takes third place among all cancers. Thus, remaining one of the frequent oncogynecological pathology, cervical cancer is a serious public health problem both in the world and in Uzbekistan.
Methods
To analyze condition of morbidity and mortality of cervical cancer we studied the state report -Information on diseases of malignant neoplasms.
Results
The average age of patients with cervical cancer was 61.3 in 2009 y, and 58.3 in 2019y. In 2009 y, the incidence rate per 100,000 population was 4.6, and in 2019 y this indicator increased to 5.6. Moreover, the highest incidence rate per 100,000 population in 2009 was observed in the Republic of Karakalpakstan, Tashkent city, Namangan, Andijan and Khorezm regions with indicators of 7.3; 7.0; 6.3; 5.8 and 5.7 per 100,000 population respectively, and the lowest in Surkhandarya (2.2), Kashkadarya (2.8) and Jizzakh (3.2) regions. In comparison of 2019 y, the highest incidence rate per 100,000 population was in Tashkent, the Republic of Karakalpakstan, Namangan and Khorezm regions with indicators of 11.8; 7.3; 6.8 and 6.5, respectively, and the lowest was observed in Kashkadarya (4.3), Samarkand (3.7) and Surkhandarya (2.8) regions. According to mortality rates, it was showed that there was growth of this indicator from 2.0 per 100,000 population in 2009 y to 3.0 per 100,000 population in 2019 y. Relatively high mortality rate per 100,000 population in 2009 y was observed in Tashkent (4.2), Khorezm (3.4) and Tashkent (2.9) regions, and in 2019 in the Republic of Karakalpakistan, Namangan and Khorezm regions with indicators of 5.8; 5.1 and 4.8, respectively.
Conclusions
In conclusion it can be shown that cervical cancer has a tendency to increase both morbidity and mortality in the Republic of Uzbekistan. The increase in morbidity is due to the intensive work of primary medical care, implementation of modern diagnostic methods, creation and use of diagnostic and treatment standards, and screening programs.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
372P - Treatment patterns and outcomes in stage III non-small cell lung cancer (NSCLC): Real-world experience in Singapore from the KINDLE study
Presenter: Ross A. Soo
Session: e-Poster Display Session
373P - Chromatin accessibility reveals potential prognostic value of the peak set associated with smoking history in patients with lung adenocarcinoma
Presenter: Jianlian Deng
Session: e-Poster Display Session
384P - BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC
Presenter: Stefanie Schalm
Session: e-Poster Display Session
385P - Patient reported outcomes (PROs) analysis for patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) receiving entrectinib in the global phase II STARTRK-2 study
Presenter: Fabrice Barlesi
Session: e-Poster Display Session
386P - A single-arm phase Ib study of autologous cytokine-induced killer (CIK) cell immunotherapy in combination with sintilimab plus chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)
Presenter: LI Zhou
Session: e-Poster Display Session
387P - Phase Ib study of savolitinib ± osimertinib in Japanese patients (pts) with advanced solid malignancies & EGFRm NSCLC: TATTON part C
Presenter: Tomonori Hirashima
Session: e-Poster Display Session
388P - Biosimilar TAB008 compared with bevacizumab in advanced non-squamous, non-small cell, EGFR wildtype lung cancer patients
Presenter: Zhen Zhou
Session: e-Poster Display Session
389P - Updated analysis from the KEYNOTE-042 China study: 1L pembrolizumab (pembro) vs chemotherapy (chemo) in Chinese patients (pts) with advanced NSCLC with PD-L1 TPS ≥1%
Presenter: Yi-Long Wu
Session: e-Poster Display Session
391P - Economic impact of next-generation sequencing (NGS) versus single-gene testing modalities to detect genomic alterations (GAs) in metastatic non-small cell lung cancer (mNSCLC) in Asia
Presenter: Herbert Loong
Session: e-Poster Display Session
392P - Clinical data from the real world: Efficacy analysis of ceritinib (450mg) in ALK-positive non-small cell lung cancer patients with brain metastases in China
Presenter: Zhixin Qiu
Session: e-Poster Display Session